



**INTERNATIONAL JOURNAL OF
PHARMA PROFESSIONAL'S
RESEARCH**



Combination Therapies in Depression: Evaluating the Synergy of Antidepressants and Adjunctive Treatments

*¹Anjali Rana, ¹Prabhjeet Kaur Bamrah, ²Priyanka, ¹Harsh Gautam
Department of Pharmaceutical Sciences, KUK
Guru Nanak Institute of Technology, Mullana, Ambala

ABSTRACT

Combination therapies in the treatment of depression have become more prominent due to their ability to improve therapeutic outcomes beyond what can be achieved with antidepressant monotherapy. This review examines the synergistic impacts of combining antidepressants with adjuvant interventions, such as psychotherapy, medication, dietary supplements, and lifestyle adjustments. The objective is to assess the effectiveness, safety, and underlying mechanisms of various combinations, providing insights into their therapeutic implications. The review evaluates the efficacy of various combination methods in different patient populations by analyzing evidence from clinical trials, meta-analyses, and longitudinal investigations. The study investigates the mechanisms of synergy, which include interactions at the pharmacodynamic level, complementarity at the psychological level, and pathways in the neurobiological system. The article also covers discussions on patient profiles, personalized medicine techniques, and strategies for managing treatment-resistant depression. This review focuses on the safety and tolerability of combination therapy, specifically discussing important findings from recent literature. Future research directions are proposed, with an emphasis on the necessity to further investigate developing medicines and identify predictive biomarkers to improve treatment outcomes. This review emphasizes the evolving landscape of combination therapies in depression management. It offers doctors evidence-based insights to help them make treatment decisions and improve patient care.

Keywords: Biomarkers, Depression, Antidepressants, Adjunctive Treatments, Synergy, Treatment, Resistant Depression, Personalized Medicine

Corresponding Author-

Anjali Rana

Email: Anjuuli66@gmail.com

Department of Pharmaceutical Sciences, KUK

Volume 15, Issue 3, 2024, Received: 1 April 2024, Accepted: 27 June 2024, Published: 30 July 2024,

DOI: 10.69580/IJPPR.15.3.2024.1-17

1. Introduction

Depression is an intricate and diverse mental health illness that impacts a large number of individuals globally. Marked by enduring feelings of sadness, diminished enjoyment or interest in activities, and a range of mental and physical difficulties, it can greatly hinder one's ability to operate on a daily basis. Conventional treatments mainly consist of pharmacotherapy, which involves using antidepressant medications like SSRIs, SNRIs, TCAs, and MAOIs to correct imbalances in neurotransmitters. Psychotherapy, such as cognitive-behavioral therapy (CBT), interpersonal therapy (IPT), and psychodynamic therapy, is also used to modify unhealthy thought patterns and enhance emotional regulation. Nevertheless, a significant number of patients exhibit insufficient response or relapse, which has sparked interest in the use of combination therapy.^{1,2} Combination therapies refer to the utilization of two or more treatment methods at the same time or in succession to improve the effectiveness of treatment by targeting numerous pathways, boosting the cooperative effect of treatment, and shortening the time required to achieve a response. These options may involve combining different medications, such as pairing an SSRI with an atypical antipsychotic, integrating medication with structured psychotherapy sessions, combining different therapeutic approaches like CBT and mindfulness-based cognitive therapy (MBCT), and incorporating innovative treatments such as transcranial magnetic stimulation (TMS) or lifestyle modifications.^{3,4} Research has demonstrated encouraging findings, suggesting that specific combinations of treatments can result in more favorable outcomes compared to using a single medication, especially in cases of treatment-resistant depression. Although combination therapies offer possible advantages, they also pose difficulties such as heightened intricacy and expenses, greater likelihood of negative side effects and drug interactions, and variability in patient willingness to accept and adhere to the treatment. Combination therapies have the potential to improve therapeutic outcomes, reduce time to response, and enhance overall patient well-being by addressing the various aspects of depression in a coordinated manner. However, it is crucial to conduct further research and carefully consider clinical factors in order to optimize these strategies.^{5,6}

1.1 Importance and Scope

Combination therapies in depression are highly significant and provide a wide range of possibilities in the realm of mental health therapy. These therapies are crucial because depression is a complex condition influenced by diverse biological, psychological, and environmental components, typically requiring a comprehensive therapy approach for optimal management. Combination therapies seek to improve therapeutic effectiveness by simultaneously targeting multiple underlying mechanisms through the integration of various treatment modalities, including pharmacotherapy, psychotherapy, and innovative interventions such as transcranial magnetic stimulation (TMS) or lifestyle modifications. Adopting this complete strategy can result in improved outcomes, quicker alleviation of symptoms, and a decrease in the overall impact of depression on individuals and society.⁷

Combination therapies offer a broad range of applications, including patients with treatment-resistant depression who have not had sufficient response to standard monotherapies. Healthcare practitioners can enhance the level of care they deliver by customizing these integrated methods to meet the specific requirements of different patient populations, resulting in more individualized and efficient treatment. Personalization is essential for addressing the diverse character of depression and enhancing treatment adherence and patient satisfaction. Although combination therapies face obstacles such as heightened intricacy, expenses, and the possibility of negative effects or drug interactions, their wider implementation encompasses inventive approaches aimed at maximizing therapeutic results and improving long-term mental well-being.^{8,9}

To summarize, combination therapies in depression are significant and extensive since they have the potential to tackle the intricate and diverse characteristics of the condition by employing a synergistic strategy. These therapies have the potential to greatly enhance the quality of life for many people by providing a comprehensive, efficient, and tailored treatment approach, highlighting their crucial role in the progress of mental healthcare.

1.2 Challenges and Opportunities

Combination therapies in depression present both significant challenges and opportunities. The challenges include increased complexity in managing multiple treatments, higher costs due to the need for multiple medications or therapies and additional monitoring, and the heightened risk of adverse effects and drug interactions. Patient adherence can also be problematic, as the demands of managing a multifaceted treatment plan may lead to decreased compliance. Furthermore, effective implementation requires clinicians to have specialized knowledge and training in multiple treatment modalities, which can be a limiting factor in some healthcare settings. Despite these challenges, combination therapies offer substantial opportunities. They have the potential to enhance treatment efficacy by targeting multiple pathways involved in depression, leading to more comprehensive symptom relief and improved outcomes. These therapies allow for a more personalized treatment approach, addressing the unique needs of each patient and improving satisfaction and adherence. For those with treatment-resistant depression, combination therapies provide an alternative that can offer relief when traditional monotherapies fail. The synergistic effects of combining treatments can create a more significant impact than individual therapies

alone. Additionally, the development of combination therapies drives ongoing research and innovation, leading to new treatment combinations and advancements in understanding depression. By adopting a holistic approach, these therapies address both the biological and psychological aspects of depression, ultimately improving patients' quality of life.¹⁰⁻¹²

1.3 Types of Combination Therapies

Combination therapies for depression involve integrating different treatment modalities to enhance therapeutic outcomes. These can be broadly categorized into pharmacological combinations, psychopharmacological combinations, and integrative approaches that combine pharmacological and non-pharmacological treatments.¹³




Figure 1: Types of Combination Therapies

2. Antidepressants + Psychotherapy

Combination therapy with an antidepressant medication and a high-intensity psychological intervention, such as cognitive-behavioral therapy, is more effective than either treatment alone for the treatment of moderate to severe depression. Patients receiving combination therapy are 27% more likely to respond, defined as a 50% reduction in symptoms, compared to those receiving psychotherapy alone, and 25% more likely to respond compared to those receiving drug treatment alone. Combination therapy is also more acceptable to patients, with 23% fewer dropouts compared to drug treatment alone. Psychotherapy alone is also more acceptable than drug treatment alone. The added benefit of combination therapy is greatest for those with the highest chance of responding to either therapy alone. For mild depression, there were too few studies to determine the relative effectiveness of the different approaches. These findings suggest that for patients with moderate to severe depression, combination therapy should be considered as the first-line approach, rather than antidepressants alone. When a single treatment is chosen, psychotherapy may be preferable to medication from the patient's perspective.^{14,15}

2.1 Cognitive Behavioral Therapy (CBT)

Cognitive Behavioral Therapy (CBT) is a widely used form of psychotherapy that focuses on the interconnection between thoughts, feelings, and behaviors. It aims to help individuals identify and modify negative or distorted thought patterns and behaviors to improve emotional regulation and develop effective coping strategies. CBT is typically a short-term, structured approach that employs specific techniques such as cognitive restructuring and exposure therapy. It has been proven effective in treating various mental health conditions, including depression, anxiety disorders, and PTSD. During CBT sessions, therapists work collaboratively with clients to set goals, practice new skills, and often assign homework to reinforce learning between sessions. The evidence-based nature of CBT, along with its practical and goal-oriented approach, has contributed to its popularity and widespread use in mental health treatment.^{16,17}

2.2 Interpersonal Therapy (IPT)

Interpersonal Therapy (IPT) is a time-limited, evidence-based psychotherapy that focuses on improving interpersonal relationships and social functioning to alleviate psychological distress. Originally developed to treat depression, IPT has since been adapted for various mental health conditions. This therapy is based on the premise that psychological symptoms often arise from or are exacerbated by difficulties in interpersonal relationships. IPT typically addresses four main areas: grief, role disputes, role transitions, and interpersonal deficits. Therapists work collaboratively with clients to identify problematic relationship patterns, improve communication skills, and develop strategies to manage interpersonal conflicts. Unlike some other forms of therapy, IPT concentrates on current relationships rather than childhood experiences or unconscious motivations. The goal is to help individuals build a stronger support network, enhance social skills, and ultimately reduce symptoms of mental health issues. IPT is usually conducted

over 12-16 weekly sessions, making it a relatively short-term intervention with a specific focus on interpersonal functioning.^{18,19}

2.3 Psychodynamic Therapy

Psychodynamic therapy is a form of depth psychology that originated from Freudian psychoanalysis but has evolved significantly over time. This approach is based on the belief that unconscious thoughts, feelings, and past experiences significantly influence a person's current behavior and mental state. In psychodynamic therapy, the therapist and client work together to uncover and understand these unconscious patterns, often by exploring childhood experiences, dreams, and the therapeutic relationship itself. The goal is to bring unconscious material into conscious awareness, helping clients gain insight into their behaviours, relationships, and emotional struggles. Unlike more structured therapies, psychodynamic therapy tends to be open-ended and can be long-term, allowing for a deep exploration of the client's psyche. Key techniques include free association, dream analysis, and the analysis of transference (the client's projection of feelings onto the therapist). While traditionally used for a wide range of psychological issues, modern psychodynamic approaches have been adapted and shown efficacy for specific conditions like depression and anxiety. The therapy aims to not only alleviate symptoms but also to foster personal growth and self-understanding.^{20,21}

3. Antidepressants + Pharmacotherapy

Antidepressants are a cornerstone of pharmacotherapy for depression and various other mental health disorders. These medications work by modulating neurotransmitter levels in the brain, primarily affecting serotonin, norepinephrine, and dopamine. Common classes include Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Pharmacotherapy with antidepressants typically involves a careful selection process based on the patient's specific symptoms, medical history, and potential side effects. Treatment often begins with a single antidepressant, with dosage adjustments made over time to achieve optimal therapeutic effect. In some cases, combination therapy using multiple antidepressants or augmentation with other classes of medications (such as mood stabilizers or antipsychotics) may be necessary for treatment-resistant depression. The full effect of antidepressants usually takes several weeks to manifest, and patients are typically advised to continue treatment for at least 6-12 months after symptom remission to prevent relapse. Throughout the course of pharmacotherapy, regular monitoring is essential to assess efficacy, manage side effects, and adjust treatment as needed. While antidepressants can be highly effective, they are often most beneficial when combined with psychotherapy and lifestyle modifications as part of a comprehensive treatment approach for depression and related disorders.^{22,23}

3.1 Mood Stabilizers (e.g. Lithium)

Mood stabilizers are a class of psychiatric medications primarily used to treat bipolar disorder and other mood disorders characterized by extreme emotional fluctuations. Lithium, the prototypical mood stabilizer, has been used for decades and remains a first-line treatment for bipolar disorder. These medications work by helping to regulate neurotransmitter activity in the brain, thereby reducing the frequency and severity of manic, hypomanic, and depressive episodes. Besides lithium, other mood stabilizers include certain anticonvulsants (such as valproic acid, carbamazepine, and lamotrigine) and some atypical antipsychotics. Mood stabilizers are typically taken long-term to prevent mood episodes and maintain emotional stability. While effective for many patients, they can have significant side effects and require regular monitoring of blood levels and organ function, especially in the case of lithium. The choice of mood stabilizer depends on the specific symptoms, the patient's medical history, and potential side effects. These medications are usually prescribed as part of a comprehensive treatment plan that may include psychotherapy, lifestyle changes, and other interventions to manage mood disorders effectively.^{24,25}

3.2 Atypical Antipsychotics (e.g. Quetiapine)

Atypical antipsychotics, also known as second-generation antipsychotics, are a class of psychiatric medications primarily used to treat schizophrenia and bipolar disorder, but they are also prescribed for other conditions such as major depressive disorder and anxiety disorders. Quetiapine, marketed under the brand name Seroquel, is a prominent example of this class. These drugs work by modulating neurotransmitter activity in the brain, particularly dopamine and serotonin systems. Atypical antipsychotics are called "atypical" because they have a different side effect profile compared to older, typical antipsychotics, with a lower risk of extrapyramidal symptoms (movement disorders). However, they can still cause significant side effects, including weight gain, metabolic changes, and sedation. Other commonly prescribed atypical antipsychotics include risperidone, olanzapine, aripiprazole, and ziprasidone. These medications are often used in combination with other treatments, such as psychotherapy or mood stabilizers, to manage complex psychiatric conditions. The choice of atypical antipsychotic depends on the specific symptoms, the patient's medical history, and potential side effects. Regular monitoring is necessary to ensure efficacy and manage potential long-term health risks associated with these medications.^{26,27}

3.3 Anxiolytics (e.g. Benzodiazepines)

Anxiolytics are a class of medications primarily used to treat anxiety disorders, with benzodiazepines being one of the most well-known types. These drugs work by enhancing the effect of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity, thereby producing a calming effect. Benzodiazepines, such as diazepam (Valium), alprazolam (Xanax), and lorazepam (Ativan), are fast-acting and effective for acute anxiety relief. However, they carry risks of dependence and withdrawal, especially when used long-term. As a result, they are typically prescribed for short-term use or as needed for panic attacks. Other anxiolytics include buspirone, which works differently from benzodiazepines and has a lower risk of dependence, and certain antidepressants that also have anti-anxiety effects. While anxiolytics can provide rapid relief from anxiety symptoms, they are often used as part of a comprehensive treatment plan that

includes psychotherapy, lifestyle changes, and potentially other medications. The choice of anxiolytic depends on the specific anxiety disorder, the patient's medical history, and the potential for side effects or dependence. Due to the risks associated with benzodiazepines, there's an increasing trend towards using alternative treatments for long-term anxiety management.^{28,29}

4. Antidepressants + Nutritional Supplements

Antidepressants are a primary pharmacological treatment for depression and certain anxiety disorders, working by modulating neurotransmitter levels in the brain. While effective for many patients, they can sometimes have side effects or may not fully alleviate symptoms. In recent years, there has been growing interest in complementing antidepressant therapy with nutritional supplements to potentially enhance treatment efficacy or mitigate side effects. Common supplements studied in this context include omega-3 fatty acids, S-adenosylmethionine (SAMe), folate, vitamin D, and St. John's Wort. Some research suggests that these supplements may have mood-enhancing properties or could help address nutritional deficiencies that may contribute to depression. For instance, omega-3 fatty acids have shown promise in potentially augmenting the effects of antidepressants, while folate supplementation may be beneficial for patients with low folate levels. However, it's crucial to note that the evidence for many of these supplements is mixed, and they should not be considered a replacement for prescribed antidepressants. Moreover, some supplements can interact with antidepressants or other medications, potentially causing adverse effects. Therefore, any use of nutritional supplements alongside antidepressants should be discussed with and monitored by a healthcare professional to ensure safety and appropriateness for the individual patient's needs.³⁰⁻³²

4.1 Omega-3 Fatty Acids

Omega-3 fatty acids are essential polyunsaturated fats crucial for human health, encompassing three main types: EPA, DHA, and ALA. EPA and DHA are primarily found in fatty fish, while ALA is abundant in plant sources like flaxseeds and walnuts. These nutrients play vital roles in heart health, brain function, and reducing inflammation throughout the body. Research suggests they may offer benefits for cardiovascular disease prevention, cognitive health, and mental well-being, including potential positive effects on depression and anxiety. While the body can convert ALA to EPA and DHA, this process is inefficient, making direct consumption of EPA and DHA beneficial. Health experts often recommend a daily intake of 250-500 mg of combined EPA and DHA for adults. Omega-3 supplements, available as fish oil, krill oil, or algae-based options, are popular for those unable to consume sufficient amounts through diet alone. As ongoing research continues to explore their potential health benefits, many nutritionists advocate for increasing omega-3 intake to balance the typically high omega-6 consumption in modern diets, aiming for a healthier fatty acid ratio.^{33,34}

4.2 S-Adenosylmethionine (SAMe)

S-Adenosylmethionine (SAMe) is a naturally occurring compound in the body that plays a crucial role in numerous biochemical processes. Synthesized primarily in the liver from methionine and

ATP, SAME functions as a major methyl donor, facilitating various methylation reactions essential for cellular function. This compound has garnered significant interest in the medical community for its potential therapeutic applications, particularly in mental health, liver function, and joint health. In the realm of mental health, SAME has been studied for its antidepressant effects, with some research suggesting it may be comparable to certain traditional antidepressants in effectiveness and potentially faster in onset of action. For liver health, SAME has shown promise in supporting liver function and has been investigated as a potential treatment for various liver diseases. Additionally, some studies indicate potential benefits for individuals with osteoarthritis. Available as an over-the-counter supplement in many countries, SAME is typically administered in doses ranging from 400 to 1600 mg per day. While generally considered safe, it's important to note that SAME can interact with certain medications, and its use should be discussed with a healthcare provider. The growing body of research on SAME continues to explore its mechanisms of action and potential applications in various health conditions.³⁵⁻³⁷

4.3 Folate and B Vitamins

Folate and B vitamins play crucial roles in mental health and overall well-being, and they are often considered in the context of dietary interventions and supplementation to support treatment for depression and other mood disorders.³⁸

- **Folate (Vitamin B9)**

- Folate, also known as folic acid in its synthetic form, is essential for DNA synthesis, repair, and methylation, as well as for amino acid metabolism. It is particularly important for brain function and mental health. Folate deficiency has been linked to depression, cognitive decline, and other psychiatric disorders. Adequate levels of folate in the body help in the synthesis of neurotransmitters such as serotonin, dopamine, and norepinephrine, which are critical for mood regulation. Some studies suggest that supplementing with folic acid can enhance the effectiveness of antidepressant medications, especially in individuals with low folate levels.³⁹⁻⁴¹

- **B Vitamins**

Vitamin B6 (Pyridoxine): Vitamin B6 is vital for the production of neurotransmitters, including serotonin, dopamine, and gamma-aminobutyric acid (GABA). It also plays a role in regulating homocysteine levels, which, when elevated, are associated with an increased risk of depression and other mental health issues.^{42,43}

Vitamin B12 (Cobalamin): Vitamin B12 is essential for maintaining healthy nerve cells and red blood cells. It is involved in the production of DNA and the synthesis of neurotransmitters. Deficiency in B12 can lead to neurological and psychiatric symptoms, including depression, memory loss, and cognitive disturbances. B12 supplementation can improve mood and cognitive function, particularly in individuals with a deficiency.⁴⁴⁻⁴⁶

Other B Vitamins: Thiamine (B1), riboflavin (B2), and niacin (B3) also contribute to overall brain health by supporting energy production, cellular function, and the synthesis of essential molecules.⁴⁷

5. Antidepressants + Lifestyle Modifications

Combining antidepressant medication with lifestyle modifications can be an effective approach to managing depression. While antidepressants help regulate brain chemistry, lifestyle changes such as regular exercise, a balanced diet, adequate sleep, stress reduction techniques, and social support can complement medical treatment. Exercise releases endorphins and improves mood, while a nutritious diet supports overall brain health. Establishing a consistent sleep schedule helps regulate emotions and energy levels. Stress management through meditation, mindfulness, or therapy can reduce depressive symptoms. Maintaining social connections and engaging in enjoyable activities provide emotional support and a sense of purpose. It's important to work with a healthcare provider to find the right combination of medication and lifestyle changes tailored to individual needs and circumstances.^{48,49}

5.1 Exercise

Exercise provides numerous benefits for physical and mental health. It can improve mood and reduce feelings of depression, anxiety, and stress by stimulating the production of endorphins, the body's natural mood elevators. Regular physical activity also has significant cardiovascular benefits, including lowering blood pressure and reducing the risk of chronic pain conditions like back pain and fibromyalgia. Additionally, exercise improves brain function and protects memory and thinking skills, enhances sleep quality, delays skin aging, and strengthens bones and muscles, especially important as we age to prevent falls and injury. A mix of aerobic, strength, and flexibility training performed regularly (e.g. 150-300 minutes per week of moderate-intensity activity) is ideal for overall fitness and health, with even small amounts of daily activity like walking providing significant benefits.^{50,51}

5.2 Sleep Hygiene

Good sleep hygiene, a set of behavioral and environmental practices designed to promote healthy sleep, provides numerous benefits for overall health and well-being. It can aid in weight management by regulating appetite, enhance cognitive functioning and memory, improve emotional well-being by reducing the risk of anxiety and depression, support cardiovascular health by mitigating the effects of stress hormones and inflammation, and boost the immune system to reduce illness. To achieve good sleep hygiene, it is essential to establish a consistent sleep schedule, create a relaxing bedtime routine, limit light exposure, maintain a comfortable sleep environment, and avoid stimulating activities before bed. By incorporating these habits into daily life, individuals can significantly improve their sleep quality and enjoy better physical and mental health.^{52,53}

5.3 Diet

A healthy diet provides numerous benefits for overall health and well-being. It can help in maintaining a healthy weight, boosting mood, protecting heart health, reducing disease risk, enhancing cognitive function, supporting gut health, managing diabetes, and reducing cancer risk. Consuming a diet rich in nutrient-dense foods such as fruits, vegetables, whole grains, lean proteins, and healthy fats can fortify the immune system, improve cognitive function, and reduce the risk of various illnesses. Incorporating these foods into your daily routine can lead to significant health benefits, and consulting a doctor or dietitian for personalized advice can help you make the most of your dietary choices.^{54,55}

6. Mechanisms of Synergy

Combining therapies in the treatment of depression can lead to enhanced outcomes due to several synergistic mechanisms, broadly categorized into pharmacodynamic interactions, psychological and behavioral complementarity, and neurobiological effects. Pharmacodynamic interactions involve how different drugs influence each other's effects within the body, such as targeting various brain receptors for comprehensive neurotransmitter modulation, increasing neurotransmitter availability, and activating complementary pathways. Psychological and behavioral complementarity occurs when medications stabilize mood, allowing for better engagement in therapies that alter negative thought patterns and behaviors, thus promoting behavioral activation and improved therapy participation. Neurobiological effects include the enhancement of neuroplasticity, normalization of the hypothalamic-pituitary-adrenal (HPA) axis, reduction of inflammation, and rebalancing of neurotransmitter systems, leading to beneficial changes in brain function and structure. Together, these synergistic mechanisms make combination therapies a powerful approach in treating depression, often yielding better outcomes than monotherapies.^{56,57}

6.1 Efficacy and Effectiveness

The efficacy and effectiveness of combination therapies for depression have been demonstrated through various research methodologies, including clinical trials, meta-analyses, and longitudinal studies. Clinical trials and meta-analyses provide robust evidence of the benefits of combining pharmacological and psychological treatments, showing significant improvements in symptom reduction and remission rates compared to monotherapies. Meta-analyses, in particular, aggregate data from multiple studies, offering a comprehensive overview of the efficacy of combined treatments across diverse populations and settings. Longitudinal studies further support these findings by tracking patients over extended periods, illustrating sustained improvements in mental health, reduced relapse rates, and better overall functioning. These research approaches collectively highlight the superior efficacy and effectiveness of combination therapies in the long-term management of depression.^{58,59}

6.2 Safety and Tolerability

The safety and tolerability of combination therapies for depression are critical factors to consider, encompassing side effects, adverse reactions, and patient-specific considerations. While

combination therapies can enhance therapeutic outcomes, they may also increase the risk of side effects and adverse reactions due to the interaction of multiple medications. Common side effects can include gastrointestinal disturbances, weight gain, and sexual dysfunction, among others, which need to be carefully monitored. Adverse reactions may be more pronounced in certain populations, necessitating personalized treatment plans that consider a patient's medical history, co-existing conditions, and potential drug interactions. Tailoring treatments to individual patient needs helps mitigate risks and ensures that the benefits of combination therapies outweigh the potential harms, ultimately enhancing patient safety and overall treatment tolerability.^{60,61}

7. Future Directions and Research Needs

Novel approaches to treating depression aim to maximize efficacy, reduce side effects, and focus on cases that don't improve with existing treatments. Novel pharmacological compounds, such as ketamine and esketamine, have shown rapid antidepressant effects, offering hope to individuals who do not respond well to traditional treatments. Furthermore, research is still being done to determine whether psychedelics, such as psilocybin, can alleviate depressive symptoms over time after a few sessions. To more effectively target specific brain regions, neuromodulation techniques like deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS) are being enhanced. This gives those with severe or resistant to treatment depression non-pharmacological options. Personalized psychotherapies, which fuse cognitive-behavioral therapy (CBT) with digital platforms and artificial intelligence, are also making mental health help more accessible and customizable to meet individual needs.^{60,62}

In order to further personalized medicine in the treatment of depression, predictive biomarker identification and validation are critical. Biomarkers, which include genetic, epigenetic, proteomic, and neuroimaging signs, can predict an individual's response to specific medications, hence facilitating the creation of more individualized and effective treatment plans. For example, genetic variations linked to serotonin transport and metabolism may predict a better response to SSRIs, and neuroimaging biomarkers may identify individuals who will likely benefit more from neuromodulation techniques. Developing reliable prognostic biomarkers can also help identify individuals who are more likely to experience adverse reactions, enabling healthcare providers to adjust treatment plans in advance. Current investigations in this area aim to improve treatment strategies, improve patient outcomes, and usher in a new era of accurate psychiatry for the treatment of depression. Setting these next steps as top priorities will help the field of depression treatment get closer to more advanced, customized, and comprehensive healthcare that addresses the complex and varied nature of depressive disorders.⁶³⁻⁶⁵

8. Conclusion

The combination of pharmacological and psychological therapies for depression has demonstrated enhanced efficacy and effectiveness through various mechanisms, including pharmacodynamic interactions, psychological and behavioral complementarity, and neurobiological effects. Clinical trials, meta-analyses, and longitudinal studies consistently show that combined treatments offer superior outcomes to monotherapies. However, attention to safety, tolerability, side effects, and

patient-specific considerations is crucial for optimizing treatment. Future research should focus on emerging therapies and predictive biomarkers to further personalize and improve depression management. Clinically, adopting a multidisciplinary approach that incorporates both established and innovative therapies, while tailoring interventions to individual patient profiles, is recommended to maximize therapeutic benefits and minimize risks.

9. Conflict of interest

The authors have no conflict of interest.

10. Acknowledgement

Authors are highly thankful to their Universities/Colleges for providing library facilities for the literature survey.

References

1. Dafer RM, Rao M, Shareef A, Sharma A. Poststroke depression. *Top Stroke Rehabil.* 2008;15(1):13-21. doi:10.1310/tsr1501-13
2. Robinson RG, Spalletta G. *Poststroke Depression: A Review.* Vol 55.; 2010.
3. Boshuizen J, Peeper DS. Rational Cancer Treatment Combinations: An Urgent Clinical Need. *Mol Cell.* 2020;78(6):1002-1018. doi:10.1016/j.molcel.2020.05.031
4. Mokhtari RB, Homayouni TS, Baluch N, et al. *Combination Therapy in Combating Cancer Systematic Review: Combination Therapy in Combating Cancer Background.* Vol 8.; 2017. www.impactjournals.com/oncotarget
5. Al-Harbi KS. Treatment-resistant depression: Therapeutic trends, challenges, and future directions. *Patient Prefer Adherence.* 2012;6:369-388. doi:10.2147/PPA.S29716
6. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: Prepared by the American thyroid association task force on thyroid hormone replacement. *Thyroid.* 2014;24(12):1670-1751. doi:10.1089/thy.2014.0028
7. Wang P. et al. Use of antipsychotics in the treatment of depressive disorders. Published online 2013.
8. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. *New England Journal of Medicine.* 2022;387(18):1637-1648. doi:10.1056/nejmoa2206443
9. van Rooij SJH, Arulpragasam AR, McDonald WM, Philip NS. Accelerated TMS - moving quickly into the future of depression treatment. *Neuropsychopharmacology.* 2024;49(1):128-137. doi:10.1038/s41386-023-01599-z
10. Cui L, Li S, Wang S, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. *Signal Transduct Target Ther.* 2024;9(1). doi:10.1038/s41392-024-01738-y
11. Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: a major unsolved challenge. *Int J Bipolar Disord.* 2020;8(1). doi:10.1186/s40345-019-0160-1

12. Unützer J, Park M. Strategies to Improve the Management of Depression in Primary Care. *Primary Care - Clinics in Office Practice*. 2012;39(2):415-431. doi:10.1016/j.pop.2012.03.010
13. Oudega M, Bradbury E, Ramer M. *Handbook of Clinical Neurology Chapter 38-Combination Therapies Get Rights and Content.*; 2012. <https://www.sciencedirect.com/science/article/abs/pii/B9780444521378000383>
14. Efferth T. *Cancer Combination Therapies with Artemisinin-Type Drugs Graphical Abstract.*; 2017. <https://www.sciencedirect.com/science/article/abs/pii/S0006295217301818>
15. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. *Diabetes Care*. 2001;24(4):758-767. doi:10.2337/diacare.24.4.758
16. Sigurvinsdóttir AL. *Effectiveness of Cognitive Behavioral Therapy (CBT) for Child and Adolescent Anxiety Disorders across Different CBT Modalities and Comparisons: A Systematic Review and Meta-Analysis.*; 2018.
17. Turner R, Swearer Napolitano SM. *Cognitive Behavioral Therapy (CBT).*; 2010. <https://digitalcommons.unl.edu/edpsychpapers/147>
18. Msd W/, Mer /. *Group Interpersonal Therapy (IPT) For Depression Group Interpersonal Therapy (IPT) For Depression 2 Group Interpersonal Therapy (IPT) For Depression.*; 2016. www.who.int
19. Petersen I, Bhana A, Baillie K. The feasibility of adapted group-based interpersonal therapy (IPT) for the treatment of depression by community health workers within the context of task shifting in South Africa. *Community Ment Health J*. 2012;48(3):336-341. doi:10.1007/s10597-011-9429-2
20. Steinert C, Munder T, Rabung S, Hoyer J, Leichsenring F. Psychodynamic therapy: As efficacious as other empirically supported treatments? A meta-analysis testing equivalence of outcomes. *American Journal of Psychiatry*. 2017;174(10):943-953. doi:10.1176/appi.ajp.2017.17010057
21. Summers RF, Barber JP, Ther P. *Books Psychodynamic Therapy Selected Pages.*; 2024.
22. Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to pharmacotherapy for geriatric major depression. *Clin Geriatr Med*. 2014;30(3):517-534. doi:10.1016/j.cger.2014.05.002
23. Ceskova E. Current pharmacotherapy of depression – focused on multimodal/multifunctional antidepressants. *Expert Opin Pharmacother*. 2016;17(14):1835-1837. doi:10.1080/14656566.2016.1219340
24. Rybakowski JK. Mood Stabilizers: Lithium. In: *NeuroPsychopharmacotherapy*. Springer International Publishing; 2022:1493-1521. doi:10.1007/978-3-030-62059-2_45
25. Dols A, Sienaert P, Van Gerven H, et al. The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: A review. *Int Clin Psychopharmacol*. 2013;28(6):287-296. doi:10.1097/YIC.0b013e32836435e2
26. Khullar A, Chue P, Bch MB, Tibbo P. *Quetiapine and Obsessive-Compulsive Symptoms (OCS): Case Report and Review of Atypical Antipsychotic-Induced OCS*. Vol 26.; 2001.
27. Farah A. *Atypicality of Atypical Antipsychotics*. Vol 7.; 2005.

28. Kuang H, Johnson JA, Mulqueen JM, Bloch MH. The efficacy of benzodiazepines as acute anxiolytics in children: A meta-analysis. *Depress Anxiety*. 2017;34(10):888-896. doi:10.1002/da.22643
29. Lindsey A, David Nutt S. *Specific TreatmentS and DiSorderS*.; 2007.
30. Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. *J Psychiatr Res*. 2010;44(1):32-41. doi:10.1016/j.jpsychires.2009.06.003
31. Martínez-Cengotitabengoa M, González-Pinto A. *Original 8*. Vol 45.; 2017.
32. Dhingra S, Parle M. Herbal remedies and nutritional supplements in the treatment of depression: A review. *Klinik Psikofarmakoloji Bulteni*. 2012;22(3):286-292. doi:10.5455/bcp.20120729090446
33. Artemis P. S. Simopoulos-Omega-3-AJCN-1991. Published online 2006.
34. Calder PC. Omega-3 fatty acids and inflammatory processes. *Nutrients*. 2010;2(3):355-374. doi:10.3390/nu2030355
35. Anstee QM, Day CP. *S-Adenosylmethionine (SAME) Therapy in Liver Disease: A Review of Current Evidence and Clinical Utility*.; 2012.
36. Echols JC, Naidoo U, Salzman C. SAME (S-adenosylmethionine). *Harv Rev Psychiatry*. 2000;8(2):84-90. doi:10.1080/hrp_8.2.84
37. Soeken KL, Lee W lin, Barker Bausell R, Agelli M, Berman BM. *Safety and Efficacy of S-Adenosylmethionine (SAME) for Osteoarthritis A Meta-Analysis*.; 2002. www.jfponline.com
38. McNulty H, Scott JM. Intake and status of folate and related B-vitamins: Considerations and challenges in achieving optimal status. *British Journal of Nutrition*. 2008;99(SUPPL. 3). doi:10.1017/S0007114508006855
39. Winiarski JP, Rampanelli R, Bassani JC, Mezalira DZ, Jost CL. Multi-walled carbon nanotubes/nickel hydroxide composite applied as electrochemical sensor for folic acid (vitamin B9) in food samples. *Journal of Food Composition and Analysis*. 2020;92. doi:10.1016/j.jfca.2020.103511
40. Sobczyn A, Harrington DJ. Laboratory assessment of folate (Vitamin B9) status. *J Clin Pathol*. 2018;71(11):949-956. doi:10.1136/jclinpath-2018-205048
41. McNulty H, Scott JM. Intake and status of folate and related B-vitamins: Considerations and challenges in achieving optimal status. *British Journal of Nutrition*. 2008;99(SUPPL. 3). doi:10.1017/S0007114508006855
42. Vrolijk MF, Opperhuizen A, Jansen EHJM, Hageman GJ, Bast A, Haenen GRMM. The vitamin B6 paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. *Toxicology in Vitro*. 2017;44:206-212. doi:10.1016/j.tiv.2017.07.009
43. McCormick D.B. Two interconnected B vitamins_ riboflavin and pyridoxine _ Physiological Reviews. Published online 1989.
44. Robert B. R. et al. *Handbook of Vitamins*.; 2001.
45. Andrès E, Loukili NH, Noel E, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. *CMAJ Canadian Medical Association Journal*. 2004;171(3):251-259. doi:10.1503/cmaj.1031155

46. Wolffenbuttel BHR, Wouters HJCM, Heiner-Fokkema MR, van der Klauw MM. The Many Faces of Cobalamin (Vitamin B12) Deficiency. *Mayo Clin Proc Innov Qual Outcomes*. 2019;3(2):200-214. doi:10.1016/j.mayocpiqo.2019.03.002
47. Richter J, Vetvicka V, Kral V. *Nutrition and Immunity during Pandemic Viral Infection Zdravotní Ústav Se Sídlem v Ústí Nad Labem Czech Republic.*; 2021. <https://www.researchgate.net/publication/352796315>
48. Brinks J, Fowler A, Franklin BA, Dulai J. Lifestyle modification in secondary prevention: Beyond pharmacotherapy. *Am J Lifestyle Med*. 2017;11(2):137-152. doi:10.1177/1559827616651402
49. Sarris J, O'Neil A, Coulson CE, Schweitzer I, Berk M. Lifestyle medicine for depression. *BMC Psychiatry*. 2014;14(1). doi:10.1186/1471-244X-14-107
50. Ruegsegger GN, Booth FW. Health benefits of exercise. *Cold Spring Harb Perspect Med*. 2018;8(7). doi:10.1101/cshperspect.a029694
51. Linda S. Exercise and Hypertension. *Med Sci Sports Exerc*. 2004;36(3):533-553. doi:10.1249/01.MSS.0000115224.88514.3A
52. Bjorvatn B, Fiske E, Pallesen S. A self-help book is better than sleep hygiene advice for insomnia: A randomized controlled comparative study. *Scand J Psychol*. 2011;52(6):580-585. doi:10.1111/j.1467-9450.2011.00902.x
53. Voinescu B, Szentagotai-Tatar A. Sleep hygiene awareness: its relation to sleep quality and diurnal preference. *J Mol Psychiatry*. 2015;3(1):1. doi:10.1186/s40303-015-0008-2
54. Medawar E, Huhn S, Villringer A, Veronica Witte A. The effects of plant-based diets on the body and the brain: a systematic review. *Transl Psychiatry*. 2019;9(1). doi:10.1038/s41398-019-0552-0
55. Hou K, Wu ZX, Chen XY, et al. Microbiota in health and diseases. *Signal Transduct Target Ther*. 2022;7(1). doi:10.1038/s41392-022-00974-4
56. Murray JL, Connell JL, Stacy A, Turner KH, Whiteley M. Mechanisms of synergy in polymicrobial infections. *Journal of Microbiology*. 2014;52(3):188-199. doi:10.1007/s12275-014-4067-3
57. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. *Lancet Oncol*. 2015;16(13):e498-e509. doi:10.1016/S1470-2045(15)00007-8
58. Kamenov K, Twomey C, Cabello M, Prina AM, Ayuso-Mateos JL. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: A meta-analysis. *Psychol Med*. 2016;47(3):414-425. doi:10.1017/S0033291716002774
59. Noetel M, Sanders T, Gallardo-Gómez D, et al. Effect of exercise for depression: Systematic review and network meta-analysis of randomised controlled trials. *BMJ*. Published online 2024. doi:10.1136/bmj-2023-075847
60. Marder SR, Mcquade RD, Stock E, et al. *Aripiprazole in the Treatment of Schizophrenia: Safety and Tolerability in Short-Term, Placebo-Controlled Trials.*; 2003. <https://www.sciencedirect.com/science/article/abs/pii/S0920996403000501>

61. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. *Clinical and Experimental Allergy*. 2009;39(6):788-797. doi:10.1111/j.1365-2222.2009.03214.x
62. Gallagher B, Foley M, Slattery CM, Gusciute G, Shanahan E, McLoughlin DM. Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial). *HRB Open Res*. 2020;3:90. doi:10.12688/hrbopenres.13182.1
63. Strawbridge R, Young AH, Cleare AJ. Biomarkers for depression: Recent insights, current challenges and future prospects. *Neuropsychiatr Dis Treat*. 2017;13:1245-1262. doi:10.2147/NDT.S114542
64. Elias E, Zhang AY, Manners MT. Novel Pharmacological Approaches to the Treatment of Depression. *Life*. 2022;12(2). doi:10.3390/life12020196
65. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. *New England Journal of Medicine*. 2022;387(18):1637-1648. doi:10.1056/nejmoa2206443